Reprogramming of Thyroid Cancer Metabolism: from Mechanism to Therapeutic Strategy

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2025 Mar 12

PMID 40069775

Authors

Yuxuan Wan

Guoqing Li

Gaoyuan Cui

Saili Duan

Shi Chang

Affiliations

Soon will be listed here.

Abstract

Thyroid cancer as one of the most prevalent malignancies of endocrine system, has raised public concern and more research on its mechanism and treatment. And metabolism-based therapies have advanced rapidly, for the exclusive metabolic profiling of thyroid cancer. In thyroid cancer cells, plenty of metabolic pathways are reprogrammed to accommodate tumor microenvironment. In this review, we initiatively summarize recent progress in the full-scale thyroid cancer metabolic rewiring and the interconnection of various metabolites. We also discuss the efficacy and prospect of metabolic targeted detection as well as therapy. Comprehending metabolic mechanism and characteristics of thyroid cancer roundly will be highly beneficial to managing individual patients.

References

Yang F, Zhang J, Zhao Z, Liu Y, Zhao Z, Fu K . Artemisinin suppresses aerobic glycolysis in thyroid cancer cells by downregulating HIF-1a, which is increased by the XIST/miR-93/HIF-1a pathway. PLoS One. 2023; 18(4):e0284242. PMC: 10085032. DOI: 10.1371/journal.pone.0284242. View

Chen J, Hou H, Chen H, Luo Y, He Y, Zhang L . Identification of β-hydroxybutyrate as a potential biomarker for female papillary thyroid cancer. Bioanalysis. 2019; 11(6):461-470. DOI: 10.4155/bio-2018-0273. View

Morani F, Phadngam S, Follo C, Titone R, Aimaretti G, Galetto A . PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in thyroid cancer cells. J Mol Endocrinol. 2014; 53(2):247-58. DOI: 10.1530/JME-14-0118. View

Yu Y, Feng C, Kuang J, Guo L, Guan H . Metformin exerts an antitumoral effect on papillary thyroid cancer cells through altered cell energy metabolism and sensitized by BACH1 depletion. Endocrine. 2022; 76(1):116-131. DOI: 10.1007/s12020-021-02977-7. View

Diaz-Gago S, Vicente-Gutierrez J, Ruiz-Rodriguez J, Calafell J, Alvarez-Alvarez A, Lasa M . Autophagy sustains mitochondrial respiration and determines resistance to BRAF inhibition in thyroid carcinoma cells. Autophagy. 2024; 20(6):1383-1397. PMC: 11210916. DOI: 10.1080/15548627.2024.2312790. View

Aloulou A, Rahier R, Arhab Y, Noiriel A, Abousalham A . Phospholipases: An Overview. Methods Mol Biol. 2018; 1835:69-105. DOI: 10.1007/978-1-4939-8672-9_3. View

Doherty J, Cleveland J . Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013; 123(9):3685-92. PMC: 3754272. DOI: 10.1172/JCI69741. View

Bian X, Jiang H, Meng Y, Li Y, Fang J, Lu Z . Regulation of gene expression by glycolytic and gluconeogenic enzymes. Trends Cell Biol. 2022; 32(9):786-799. DOI: 10.1016/j.tcb.2022.02.003. View

Yang W, Zheng Z, Yi P, Wang S, Zhang N, Ming J . LncRNA NBR2 Inhibits the Malignancy of Thyroid Cancer, Associated With Enhancing the AMPK Signaling. Front Oncol. 2020; 10:956. PMC: 7304297. DOI: 10.3389/fonc.2020.00956. View

10.

Alexander E, Cibas E . Diagnosis of thyroid nodules. Lancet Diabetes Endocrinol. 2022; 10(7):533-539. DOI: 10.1016/S2213-8587(22)00101-2. View

11.

Ghanem N, El-Baba C, Araji K, El-Khoury R, Usta J, Darwiche N . The Pentose Phosphate Pathway in Cancer: Regulation and Therapeutic Opportunities. Chemotherapy. 2021; 66(5-6):179-191. DOI: 10.1159/000519784. View

12.

Xu Q, Wang J, Mao Y, Xuan Z, Yang K, Tang X . Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms. Neoplasia. 2024; 52:100996. PMC: 11007432. DOI: 10.1016/j.neo.2024.100996. View

13.

Yang S, Gong Z, Liu Z, Wei M, Xue L, Vlantis A . Differential Effects of Estrogen Receptor Alpha and Beta on Endogenous Ligands of Peroxisome Proliferator-Activated Receptor Gamma in Papillary Thyroid Cancer. Front Endocrinol (Lausanne). 2021; 12:708248. PMC: 8453163. DOI: 10.3389/fendo.2021.708248. View

14.

Pappa T, Alevizaki M . Obesity and thyroid cancer: a clinical update. Thyroid. 2013; 24(2):190-9. DOI: 10.1089/thy.2013.0232. View

15.

Jeon Y, Kim Y, Lee G, Kim J . Physiological and pathological roles of lipogenesis. Nat Metab. 2023; 5(5):735-759. DOI: 10.1038/s42255-023-00786-y. View

16.

Cui Y, Luo J, Bai N, Yu Z . Deltex E3 ubiquitin ligase 4 promotes thyroid cancer progression through stearoyl-CoA desaturase 1. Funct Integr Genomics. 2023; 23(3):280. DOI: 10.1007/s10142-023-01215-9. View

17.

Bose S, Le A . Glucose Metabolism in Cancer. Adv Exp Med Biol. 2018; 1063:3-12. DOI: 10.1007/978-3-319-77736-8_1. View

18.

Ma L, Cheng Q . Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming. Biochem Biophys Res Commun. 2018; 498(4):912-917. DOI: 10.1016/j.bbrc.2018.03.079. View

19.

Chen S, Bao X, Chen H, Jia M, Li W, Zhang L . Thyroid Cancer-Associated Mitochondrial DNA Mutation G3842A Promotes Tumorigenicity via ROS-Mediated ERK1/2 Activation. Oxid Med Cell Longev. 2022; 2022:9982449. PMC: 9020963. DOI: 10.1155/2022/9982449. View

20.

Kitahara C, Pfeiffer R, Sosa J, Shiels M . Impact of Overweight and Obesity on US Papillary Thyroid Cancer Incidence Trends (1995-2015). J Natl Cancer Inst. 2019; 112(8):810-817. PMC: 7825478. DOI: 10.1093/jnci/djz202. View